Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule.
49 - 57
MetadataShow full item record
PURPOSE: To establish the performance characteristics of annual transvaginal ultrasound and serum CA125 screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the impact of delayed screening interval and surgical intervention. PATIENTS AND METHODS: Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated ≥ 10% lifetime risk of OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were observed prospectively by centers, questionnaire, and national cancer registries. RESULTS: Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI, 54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7% to 98.5%) if they were classified as true positives. Positive and negative predictive values of incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100) respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared with women screened in the year before diagnosis, those not screened in the year before diagnosis were more likely to have ≥ stage IIIc disease (85.7% v 26.1%; P = .009). Screening interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC. CONCLUSION: These results in the high-risk population highlight the need for strict adherence to screening schedule. Screening more frequently than annually with prompt surgical intervention seems to offer a better chance of early-stage detection.
AuthorsRosenthal, AN; Fraser, L; Manchanda, R; Badman, P; Philpott, S; Mozersky, J; Hadwin, R; Cafferty, FH; Benjamin, E; Singh, N; Evans, DG; Eccles, DM; Skates, SJ; Mackay, J; Menon, U; Jacobs, IJ
- College Publications 
Showing items related by title, author, creator and subject.
Miranda-Lorenzo, I; Dorado, J; Lonardo, E; Alcala, S; Serrano, AG; Clausell-Tormos, J; Cioffi, M; Megias, D; Zagorac, S; Balic, A;... (2014-11)Cancer stem cells (CSCs) are thought to drive tumor growth, metastasis and chemoresistance. Although surface markers such as CD133 and CD44 have been successfully used to isolate CSCs, their expression is not exclusively ...
In1-ghrelin, a splice variant of ghrelin gene, is associated with the evolution and aggressiveness of human neuroendocrine tumors: Evidence from clinical, cellular and molecular parameters. Luque, RM; Sampedro-Nuñez, M; Gahete, MD; Ramos-Levi, A; Ibáñez-Costa, A; Rivero-Cortés, E; Serrano-Somavilla, A; Adrados, M; Culler, MD; Castaño, JP;... (2015-06-18)Ghrelin system comprises a complex family of peptides, receptors (GHSRs), and modifying enzymes [e.g. ghrelin-O-acyl-transferase (GOAT)] that control multiple pathophysiological processes. Aberrant alternative splicing is ...
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium. Goranova, T; Ennis, D; Piskorz, AM; Macintyre, G; Lewsley, LA; Stobo, J; Wilson, C; Kay, D; Glasspool, RM; Lockley, M;... (Springer Nature on behalf of Cancer Research UK., 2017-03-30)BACKGROUND: Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian ...